Japan incentivizing its companies to shift manufacturing facilities out of China and adding Bangladesh to a list of preferred destinations for relocating the factories might give the nation’s economy a boost.
“As the COVID-19 pandemic started in China, Japanese companies needed to diversify” their supply chains further, Japanese Ambassador to Bangladesh Naoki Ito said in an interview. “This will provide an opportunity for Bangladesh.”
Japan’s nudge to relocate companies comes at a time when a special economic zone (SEZ) is being developed in Bangladesh to attract Japanese firms’ production facilities.
The industrial zone sprawling on 405 hectares in the Araihazar sub-district, 32km from the capital Dhaka, is expected to bring in US$20 billion in Japanese investment, the Bangladesh Economic Zones Authority said.
For years, Japanese manufacturers have sought lower labor costs and supply-chain diversification by moving some output out of China, as wages rose and infrastructure in countries like Vietnam and Bangladesh improved.
Over the past 10 years, the number of Japanese companies operating in Bangladesh has tripled to about 300, Ito said.
Japan has allocated US$350 million in special loans to set up the US$1 billion industrial zone, making it the largest such assistance for an SEZ in Asia, Ito added.
The Araihazar Industrial Park, which is to be operational by next year, is seeking to draw new investments from automakers, such as Suzuki Motor Corp and Mitsubishi Corp, Ito said.
Japan Tobacco Inc and Honda Motor Co are so far among the largest Japanese investors in Bangladesh.
The nation occupies a geographically strategic location linking South Asia and Southeast Asia, and Japan is planning a 177.77 billion taka (US$2.1 billion) deep-sea port on Matarbari Island.
One of the world’s most populous countries, Bangladesh has 160 million people residing in a land area that is about 40 percent of Japan.
Bangladesh’s economy, which grew an estimated 5.2 percent in the year ended in June last year, is expected to expand 7.4 percent in the current financial year.
While that is slower than the 8.2 percent pace previously forecast, it still puts the nation ahead of regional peers on the growth metric.
The country nestled between India and the Bay of Bengal is a destination with “good and strong” prospects for Japanese companies, Ito said.
“The pace of recovery is faster in Bangladesh, compared with neighboring countries,” Ito added.
The US dollar on Friday rose against the euro, but pared gains late in a session that was muddied by quarter-end trading, while riskier commodity-led currencies fell sharply after European inflation hit a record high and US consumer spending increased faster than expected. Although the dollar index was showing its biggest quarterly gain since the first quarter 2015, but was registered its first weekly decline in three weeks. Sterling rose against the dollar after falling earlier in the day. The pound last showed four straight sessions of gains followed by wild declines on concerns about Britain’s plan to slash taxes and pay
SAMSUNG DISTANT SECOND: Top local chip fims served nearly two-thirds of the global market in Q2, while Samsung kept South Korea competitive with its 16.5 percent share Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) remained the world’s largest contract chipmaker in the second quarter of the year with a 53.4 percent share of the global pure-play foundry market, the Taipei-based market information advisory firm TrendForce Corp (集邦科技) said in a research report on Tuesday. Despite TSMC’s market share dipping slightly from 53.6 percent in the first quarter, it was still far ahead of its rivals, TrendForce said. TSMC continued to benefit from emerging technologies, such as high-performance computing devices, the Internet of Things and automotive electronics, as it posted US$18.15 billion in sales in the second quarter, up 3.5 percent
Moderna Inc has refused to hand over to China the core intellectual property behind the development of its COVID-19 vaccine, leading to a collapse in negotiations on its sale in the country, the Financial Times reported on Saturday, citing people familiar with the matter. The Cambridge, Massachusetts-based pharmaceutical company turned down China’s request to disclose the formula for its mRNA vaccine because of commercial and safety concerns, the newspaper said, citing people involved in negotiations that took place from 2020 to last year, adding that the vaccine maker is still “eager” to sell the product to China. The company had “given up”
PRICE POINT: While overall demand has lagged expectations, higher-priced iPhone 14 Pro models appear to attract more attention than entry-level versions, sources said Apple Inc is backing off plans to increase production of its new iPhones this year after an anticipated surge in demand failed to materialize, people familiar with the matter said. The Cupertino, California-based company has told suppliers to pull back from efforts to increase assembly of the iPhone 14 product family by as many as 6 million units in the second half of this year, said the people, asking not to be named as the plans are not public. Instead, the company would aim to produce 90 million handsets for the period, about the same level as in the second half
RSS